Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
Profile
Business Description
Company Info
Address:
4902 Eisenhower Blvd.
Suite 125
Tampa, FL 33634
Telephone:
813-286-7900
Fax:
813-286-7904
Email:
info@oragenics.com
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical Preparations (2834)